Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium
نویسندگان
چکیده
Background: Routine human papillomavirus (HPV) immunization in Belgium is currently regionally managed, with school-aged girls receiving the 9-valent HPV (9vHPV) vaccine Flanders and Wallonia-Brussels a national catch-up program for females only. This study will assess whether expanding these programs to gender-neutral vaccination (GNV) 9vHPV cost-effective strategy Belgium. Methods: A validated HPV-type transmission dynamic model estimated potential health economic impact of regional programs, comparing GNV versus female-only (FOV) individuals aged 11–12 years Flanders, FOV 2-valent (2vHPV) 12–13 Wallonia-Brussels, those 12–18 years. Vaccination coverage rates 90, 50, 50% both males were used base cases three respectively, sensitivity analyses conducted. All costs are from third-party payer perspective, outcome measures reported over 100-year time horizon. Results: was projected decrease cumulative incidence 6/11/16/18/31/33/45/52/58-related diseases relative Wallonia-Brussels. Further reductions also vaccine, including 6.8% (2,256 cases) cervical cancer, 7.1% (386 18.8% (2,784 head neck cancer males, 30.3% (82,103 44.6% (102,936 genital warts respectively. As result, would lead HPV-related deaths. Both strategies reduce disease be compared incremental cost-effectiveness ratios €8,062, €4,179, €6,127 per quality-adjusted life-years Sensitivity consistent cases. Conclusions: can burden
منابع مشابه
Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
BACKGROUND Current prophylactic vaccines against human papillomavirus (HPV) target two of the most oncogenic types, HPV-16 and -18, which contribute to roughly 70% of cervical cancers worldwide. Second-generation HPV vaccines include a 9-valent vaccine, which targets five additional oncogenic HPV types (i.e., 31, 33, 45, 52, and 58) that contribute to another 15-30% of cervical cancer cases. Th...
متن کاملCost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
BACKGROUND The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical intraepithelial neoplasia (CIN), genital warts and other HPV-related diseases. OBJECTIVE To determine the cost effectiveness of providing a quadrivalent (6,11,16,18) HPV vaccine programme in adolescent females aged 12...
متن کاملCost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands
jnci.oxfordjournals.org JNCI | Articles 1083 Multiple analyses of the cost-effectiveness of vaccination against the human papillomavirus (HPV) have concluded that vaccination should be cost-effective ( 1 – 6 ). However, this conclusion mainly depends on the incidence and mortality rates of cervical cancer. Low incidence and mortality rates imply a limited maximum effect of HPV vaccination. The ...
متن کاملThe Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
Objective: National cervical cancer prevention program has been initiated in Indonesia since April 2015 and the ministry of health has started efforts to integrate the HPV Vaccine in the national immunization program since Q4 2015. Thus, it becomes important to analyze the cost-effectiveness of HPV vaccine. The objective of this model is to examine the potential long-term epidemiologic and econ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Pharmacology
سال: 2021
ISSN: ['1663-9812']
DOI: https://doi.org/10.3389/fphar.2021.628434